News Focus
News Focus
Post# of 257302
Next 10
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

Re: Bickema post# 217231

Monday, 02/12/2018 9:38:08 AM

Monday, February 12, 2018 9:38:08 AM

Post# of 257302

...specific segments of business, HCV, Nash, RSV, HBV.

ENTA is no longer doing drug development in HCV, so the HCV portion of the company's intrinsic value consists of the passive royalty stream from ABBV. Hence, your question boils down to the value of each of the two virtual companies described in #msg-138369686.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today